OncoSec Medical Inc (ONCSQ)

[guti]

previous to Oncosec receiving their FDA Breakthrough Therapy Designation, 35 fast tracks were given to companies from Jan.6 2016 to Jan.31 2017. The best thing about a fast track to an investor is that it equates to more future revenue that can be made from the product from the time saved in the study. They will most likely create a study with a much larger population that includes both non-responders to anti-PD-1 and PD-L1 therapies. They will need some extra funds for this, as well as the help from Merck for additional Keytruda. It would seem that it is to their best interest to start paying attention to the study if results continue positive.

In the mean time, the market will value the shares according to the amount of cash at hand, which means at present time it is slightly over valued. They will need money to allow the share price to rise and with a fast track it should not be difficult to attain.

Keeping it on topic.